Biopharma Almirall 9M sales rise on European dermatology growth

By Reuters News


Overview

  • Spain biopharma's 9M 2026 net sales rose 8.3% yr/yr, led by European dermatology growth

  • EBITDA for 9M 2026 grew 22.7% yr/yr, margin at 24.9%

  • Company reiterated full-year 2026 guidance for net sales and EBITDA


Outlook

  • Almirall reiterates 2026 guidance for 9-12% net sales growth

  • Company expects 2026 EBITDA between €270 mln and €290 mln


Result Drivers

  • EUROPEAN DERMATOLOGY - Co said 9M sales in its European dermatology business grew 17.6% yr/yr, driven by continued momentum in key products

  • BIOLOGICS PORTFOLIO - Sales of Ebglyss rose 75% yr/yr to €132.1 mln and Ilumetri up 11.5% to €190.6 mln, with Ebglyss gaining market share and supported by new long-term data

  • BROAD DERMATOLOGY PORTFOLIO - Wynzora sales rose 15.4% to €29.3 mln and Klisyri up 18.4% to €23.8 mln, contributing to overall growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Sales

EUR 889.20 mln

9M EBITDA

EUR 221.70 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Almirall, S.A. is €14.13, about 26% above its November 6 closing price of €11.22

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago


Reuters Recommended Reads

  • Nov 6 - India's Gland Pharma beats quarterly estimates on strong Europe, US sales

  • Nov 6 - Moderna swings to Q3 profit, raises outlook on strong COVID vaccine demand

  • Nov 6 - European stainless steelmakers see recovery pushed further into 2027


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.